TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01026324
Drug: dinaciclib
Normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00869700
Drug: Artemether/Lumefantrine
Normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria
Study: NCT00238641
Drug: Botulinum Toxin type B
Normalized name: Botulinum toxin type B
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04522830
Drug: BTL-TML-COVID
Normalized name: BTL-TML-COVID
DrugBank: Thimerosal (DB11590)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.
Study: NCT02162381
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single dose of methylphenidate 10 mg to be taken orally in the morning
Study: NCT03699956
Drug: Cisplatin/carboplatin plus etoposide
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care platinum doublet chemotherapy
Study: NCT03733301
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT03365869
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus or placebo were added to patients every day
Study: NCT00483119
Drug: intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
Study: NCT04668066
Drug: PF-07242813
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07242813 given intravenously or subcutaneous
Study: NCT04254913
Drug: MT-1186
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension
Study: NCT02685137
Drug: stannsoporfin
Normalized name: Stannsoporfin
DrugBank: Stannsoporfin (DB04912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of stannsoporfin to treat jaundice.
Study: NCT03156296
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
Study: NCT03156296
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
Study: NCT00707941
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25
Study: NCT02036853
Drug: Triheptanoin
Normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (\~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (\~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established.
Study: NCT03704285
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
Study: NCT01742286
Drug: Ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat.
Study: NCT01134705
Drug: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
Normalized name: beclomethasone dipropionate Nasal Product
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
Study: NCT03886311
Drug: Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks
Study: NCT01573052
Drug: Chlordiazepoxide
Normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg four times daily x 3 days then tapered over 3 days
Study: NCT01573052
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg four times daily x 3 days then tapered over 3 days
Study: NCT01779466
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03944252
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
Study: NCT03944252
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
Study: NCT01215097
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once a day
Study: NCT00695097
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab infusion on Day 1 and Day 15
Study: NCT00695097
Drug: No Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No Rituximab
Study: NCT02302339
Drug: glembatumumab vedotin
Normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02302339
Drug: glembatumumab vedotin and varlilumab
Normalized name: Brentuximab Vedotin
DrugBank: Glembatumumab vedotin (DB05996)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02302339
Drug: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Glembatumumab vedotin (DB05996)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02302339
Drug: glembatumumab vedotin and CDX-301
Normalized name: CDX
DrugBank: Glembatumumab vedotin (DB05996)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02014337
Drug: Mifepristone and Eribulin in combination
Normalized name: mifepristone, combinations
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
Study: NCT00899431
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
Study: NCT00899431
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 intravenously daily on days -5, -4, -3.
Study: NCT00899431
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8.
Study: NCT00899431
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg intravenously over 4 hours (day -2 and -1).
Study: NCT00899431
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
Study: NCT00899431
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
Study: NCT03622476
Drug: concentrated FVIII
Normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention if the assessment considers that the treatment is inadequate
Study: NCT01193504
Drug: Pred Forte
Normalized name: Pred Forte
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pred Forte BID for 4 weeks postop
Study: NCT01193504
Drug: Lotemax
Normalized name: Lotemax
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lotemax BID for 4 weeks postop.
Study: NCT03196362
Drug: Pioglitazone + Metformin
Normalized name: metformin / pioglitazone
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One tablet of fixed dose of Pioglitazone/ Metformin (15mg/30mg) will be given twice daily
Study: NCT03756324
Drug: CHPM (Chinese Herbal Patent Medicine )
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
Study: NCT03756324
Drug: Antibiotics Cefdinir Capsules
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
Study: NCT03756324
Drug: Antibiotics Cefdinir Capsules
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
Study: NCT00077870
Drug: ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01448070
Drug: human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
Study: NCT00456859
Drug: Kremezin
Normalized name: METHYL SALICYLATE 31 g in 100 g / MENTHOL, UNSPECIFIED FORM 11 g in 100 g TOPICAL CREAM [FREEZIN COLD TOAST]
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00389168
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated to 300 mg od, 48 weeks.
Study: NCT00389168
Drug: Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated to 100 mg od, 48 weeks.
Study: NCT02203773
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
Study: NCT02203773
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
Study: NCT02203773
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
Study: NCT00101374
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04237831
Drug: BMS-986259
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT03832426
Drug: Narlaprevir
Normalized name: narlaprevir
DrugBank: Narlaprevir (DB14760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg film-coated tablets
Study: NCT03832426
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg film-coated tablets
Study: NCT02146534
Drug: extended release fampridine
Normalized name: dalfampridine Extended Release Oral Tablet
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pts will receive Fampyra 10 mg BID PO for the duration of the study
Study: NCT03807921
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral anticoagulation
Study: NCT03807921
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiplatelet treatment
Study: NCT00267813
Drug: Bupropion (Zyban)
Normalized name: BUPROPION (ZYBAN) 150MG SA TAB PACK 60
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet a day increasing to 2 tablets a day after a week
Study: NCT00077415
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00077415
Drug: triapine
Normalized name: Triapine
DrugBank: Triapine (DB11940)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02825875
Drug: 18F DCFPyL- Radiopharmaceutica
Normalized name: (18F)DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01525407
Drug: Atorvastatin Calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02974738
Drug: Belzutifan
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
Study: NCT04535518
Drug: IVIG
Normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG at a single dose of 2 g/kg
Study: NCT04535518
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
Study: NCT04535518
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
Study: NCT00566397
Drug: PF-04494700
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg for 6 days followed by daily dosing of 5mg
Study: NCT04737304
Drug: BEN2293 (0.25% or 1.0% w/w) or matching placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
Study: NCT00566397
Drug: PF-04494700
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
Study: NCT02230319
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01345357
Drug: CEP-9722
Normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
Study: NCT01495793
Drug: Rotigotine
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied.
Study: NCT01345357
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered at 1250 mg/m\^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
Study: NCT01345357
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered at 75 mg/m\^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
Study: NCT01942733
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
Study: NCT01543633
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
Study: NCT02894541
Drug: CKD-519 100mg
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02894541
Drug: CKD-519 200mg
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00346970
Drug: Extended-Release Niacin
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
Study: NCT03480243
Drug: Padsevonil (UCB0942)
Normalized name: Padsevonil
DrugBank: Padsevonil (DB14977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use
Study: NCT05429749
Drug: Ferinject
Normalized name: epinephrine
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
Study: NCT04522284
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with the selected regimen will take up to a maximum duration of 12 months, in 4-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range.~Maximum total cumulative dose per cycle of Ibrutinib in the predetermined safety range is set at 100% of standard starting dose (i.e. 420 mg once daily for 4 weeks, which constitutes the total of 11760 mg per cycle). Minimum total cumulative dose per cycle of Ibrutinib in the predetermined safety range is set at 50% of the standard starting dose (i.e. 280 mg once daily on alternative days with 140 mg once daily, which constitutes the total of 5880 mg per cycle). The dosing range may be altered to suit the specific circumstances of the participant, thus giving the participant-specific safe dosing range.
Study: NCT00610454
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00616785
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00616785
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes